ABCDEFGHIJKLMNOPQRSTUVWXYZAAABAC
6
InstituteAudienceAward Type/RFA #TitlePurposeDeadlineWebsiteExpiration Date
7
NCIFacultyR01 PAR-21-190Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)This FOA supports research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.3/8/2024https://grants.nih.gov/grants/guide/pa-files/PAR-21-190.html3/8/24
8
NCIFacultyAdmin Suppl NOT-CA-24-032Administrative supplements to understand effects of within-group
heterogeneity on cancer control outcomes in underrepresented populations
The goal of this Notice of Special interest (NOSI) from the National Cancer Institute (NCI) is to support administrative supplements for currently funded investigators to better understand within-group factors that contribute to cancer prevention and control outcomes and intervention effectiveness in populations that are underrepresented in or excluded from cancer research. This administrative supplement would provide funding for one year to initiate or enhance evaluation of heterogeneity within populations and/or how this heterogeneity influences cancer outcomes, within the scope of the parent grant.4/29/2024https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-032.html4/30/24
9
NCIFacultyAdmin Suppl NOT-CA-24-030Administrative Supplements for Contemporary Modifiable ExposuresThe goal of this NOSI is to encourage currently funded NCI extramural investigators to apply for administrative supplement funds to active NCI-funded grants to support research and to advance our understanding of the impact of contemporary modifiable exposures (e.g., anti-obesity medications, cannabis use, e-cigarettes use, exposures to chemical hair relaxers, microplastics) on cancer. The goals of the administrative supplement are to support (i) the collection and assessment of contemporary modifiable exposures and/or (ii) research into the impact of these exposures on cancer across the life course and cancer control continuum. These exposures, products and their co-use have increased, but our understanding of their impact on cancer is limited.4/29/2024https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-030.html4/23/24
10
NCITraineesK22 PAR-21-318The NCI Transition Career Development Award (K22 Independent Basic Experimental Studies with Humans Required)This FOA provides protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-21-318.html3/15/24
11
NCITraineesK22 PAR-21-128and Cancer Across the Cancer Control ContinuumThis FOA provides protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-21-128.html3/15/24
12
NCITraineesK22 PAR-21-111The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required)This FOA provides protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-21-111.html3/15/24
13
NIHFacultyR01 PA-20-185NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PA-20-185.html5/8/24
14
NIHFacultyR21 PA-20-195NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/pa-20-195.html5/8/24
15
NCIJr. FacultyK12 PAR-22-136Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists trained in clinical and translational cancer research, and to promote their career development as cancer researchers. 6/17/2024https://grants.nih.gov/grants/guide/pa-files/PAR-22-136.html6/18/24
16
NCIFacultyUG3/UH3 RFA-CA-23-029Cancer Immunoprevention Network (CIP-Net) ​Research Projects (UG3/UH3 Clinical Trials Not Allowed)Through this NOFO, NCI intends to establish a Cancer Immunoprevention Network (CIP-Net) to support a deeper understanding of basic mechanisms of immunoprevention, discover novel immunoprevention strategies, preclinical development and testing of interventions, and foster a community of cancer immunoprevention researchers. 7/3/2024https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-029.html7/4/24
17
NCIJr. FacultyK08 PAR-21-300NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 - Independent Clinical Trial Not Allowed)This NCI-sponsored K08 award is specifically designed to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible clinical scientists from diverse backgrounds, including groups that have been shown to be nationally underrepresented in health-related sciences and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-21-300.html9/8/24
18
NCIJr. FacultyK08 PAR-21-299NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 - Clinical Trial Required)This NCI-sponsored K08 award is specifically designed to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible clinical scientists from diverse backgrounds, including groups that have been shown to be nationally underrepresented in health-related sciences and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-21-299.html9/8/24
19
NCITraineesK22 PAR-21-302NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)K22 funding to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-21-302.html9/8/24
20
NCIFacultyR01 PAR-24-122Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)This NOFO encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, digital health and data science, and implementation science.6/5/2024, 10/05/2024https://grants.nih.gov/grants/guide/pa-files/PAR-24-122.html11/6/24
21
NCIFacultyR01 PAR-21-329Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)This FOA supports basic, translational, and/or clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-21-329.html11/6/24
22
NCIFacultyR35 RFA-CA-22-045NCI Outstanding Investigator Award (R35 Clinical Trial Optional)The Outstanding Investigator Award (OIA) provides long-term support to accomplished investigators with outstanding records of cancer research accomplishments who propose to conduct exceptional research. 11/07/2024https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-045.html11/8/24
23
NCIJr. FacultyK01 PAR-21-296NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Clinical Trial Required)This FOA is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-21-296.html11/13/24
24
NCIJr. FacultyK01 PAR-21-295NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-21-295.html11/13/24
25
NCIFacultyR01 PAR-22-071Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are expected to mature experimental nanomedicines designed for highly relevant cancer clinical objectives with a strong potential to improve cancer treatment effectiveness.5/17/2024, 11/17/2024https://grants.nih.gov/grants/guide/pa-files/PAR-22-071.html11/18/24
26
NCIFacultyR21 PAR-22-061Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed)This FOA supports basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-22-061.html1/8/25
27
NCIFacultyR21 PAR-22-062Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)This FOA supports basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-22-062.html1/8/25
28
NCIFacultyR01 PAR-21-294Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)This FOA encourages applications that focus on developing integrated imaging approaches to interrogate the role of inflammation in cancer through strong cross-field collaboration between cancer basic science researchers and imaging scientists. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-21-294.html1/8/25
29
NCIFacultyR01 PAR-21-290Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)This FOA invites R01 grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of these modalities in the characterization of therapy response and/or emergence of treatment resistance.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-21-290.html1/8/25
30
NCIFacultySuppl PAR-22-114Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)The purpose of this FOA is to promote new cancer disparities research among investigators who do not normally conduct it and to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. 9/6/2024, 1/23/2025 https://grants.nih.gov/grants/guide/pa-files/PAR-22-114.html1/24/25
31
NIHFacultyR01 RFA-OD-23-017Tobacco Regulatory Science (R01 Clinical Trial Optional)The purpose of this Notice of Funding Opportunity (NOFO) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).5/6/2024, 10/4/2024, 5/2/2025https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-23-017.html5/5/25
32
NCIFacultyR21 PAR-22-083Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)This FOA promotes epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-22-083.html5/8/25
33
NCIFacultyR21 PAR-22-084Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)This FOA promotes epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-22-084.html5/8/25
34
NCIFacultyR01 PAR-22-085Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)This FOA solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-22-085.html5/8/25
35
NCIFacultyR21 PAR-22-086Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)This FOA solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-22-086.html5/8/25
36
NCIFacultyR01 PAR-22-139Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)This FOA solicits R01 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-22-139.html5/8/25
37
NCIFacultyR21 PAR-22-140Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)This FOA solicits R21 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-22-140.html5/8/25
38
NCIFacultyR21 PAR-22-216NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)This FOA supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-22-216.html7/2/25
39
NIHTraineesF31 PA-23-272Individual Predoctoral FellowshipFunding available only during PhD trainingStandard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PA-23-272.html9/8/25
40
NCITraineesF31 Diversity PA-23-271Individual Predoctoral Fellowship to Promote Diversity in Health-Related ResearchFunding only available during PhD training. Applicant must be from diverse backgrounds including those from groups that are underrepresented in the biomedical, behavioral, or clinical research workforce.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PA-23-271.html9/8/25
41
NCITraineesPA-23-260Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training ProgramsFunding available to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD)Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PA-23-260.html9/8/25
42
NCIFacultyR01 PAR-22-131Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)This FOA will support the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other omic information and/or meta data obtained from platforms including but not limited to lower resolution diagnostic acquisitions and systemic biomarker results to high resolution single-cell analytics / imaging applied to the characterization of heterogeneous cell populations within tumor for improving current approaches for: (1) the early detection of organ confined premetastatic aggressive cancer, and, (2) identifying precancerous lesions associated with the development of a subsequent lethal phenotype.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-22-131.html9/8/25
43
NCIFacultyR01 PAR-22-164Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)This FOA supports research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication pilot interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-22-164.html9/8/25
44
NCIFacultyR21 PAR-22-165Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)This FOA supports research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication pilot interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-22-165.html9/8/25
45
NCIFacultyR21 PAR-22-199Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)This FOA solicits R21 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-22-199.html9/8/25
46
NCIFacultyR34 PAR-22-173Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)This FOA facilitates well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-22-173.html9/8/25
47
NCIFacultyR01 PAR-22-218Biology of Bladder Cancer (R01 Clinical Trial Optional)This FOA encourages applications that investigate the biology and underlying mechanisms of bladder cancer. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-22-218.html9/8/25
48
NCIFacultyR21 PAR-22-219Biology of Bladder Cancer (R21 Clinical Trial Optional)This FOA encourages applications that investigate the biology and underlying mechanisms of bladder cancer. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-22-219.html9/8/25
49
NCIFacultyR21 RFA-CA-22-057Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed)This FOA focuses on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae.Standard dates applyhttps://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-057.html9/8/25
50
NCIFacultyU01 PAR-23-051Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed)This FOA requests applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression.2/17/2024/5, 10/23/2024/5 https://grants.nih.gov/grants/guide/pa-files/PAR-23-051.html10/24/25
51
NCIFacultyUH2 PAR-23-052Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed)This FOA requests applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression2/17/2024/5, 10/23/2024/5 https://grants.nih.gov/grants/guide/pa-files/PAR-23-052.html10/24/25
52
NCIFacultyUG3/UH3 PAR-22-256Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)This FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.2/14/2024/5, 7/14/2024/5, 11/17/2024/5https://grants.nih.gov/grants/guide/pa-files/PAR-22-256.html11/18/25
53
NCIFacultyU24 PAR-23-124Genomic Community Resources (U24 Clinical Trial Not Allowed)To facilitate genomic research and the dissemination of its products, NHGRI supports genomic resources that are crucial for basic research, disease studies, model organism studies, and other biomedical research. Awards under this FOA will support the development and distribution of genomic resources that will be valuable for the broad research community, using cost-effective approaches. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-23-124.html1/26/26
54
NCIFacultyR01 PAR-23-273Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)This NOFO will solicit mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-23-273.html5/8/26
55
NCIFacultyR21 PAR-23-152Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)This NOFO aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-23-152.html5/8/26
56
NCIFacultyR01 PAR-23-153Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)This NOFO aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-23-153.html5/8/26
57
NCIFacultyP01 PAR-23-059National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)This FOA supports investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-23-059.html5/8/26
58
NIHFacultyR01 PAR-23-254Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)This NOFO encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.).Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-23-254.html9/8/26
59
NIHFacultyR21 PAR-23-255Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)This NOFO encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.).Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-23-255.html9/8/26
60
NCIFacultyR01 PAR-23-281Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)Funding to expand, improve, or transform the utility of mammalian cancer and tumor mdoels for translational researchStandard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-23-281.html9/8/26
61
NIHFacultyP50 PAR-23-284Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)This NOFO invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-23-284.html9/26/26
62
NIHTraineesK99/R00 PAR-23-288NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.2/14/24, 6/14/24, 10/14/24https://grants.nih.gov/grants/guide/pa-files/PAR-23-288.html10/15/26
63
NIHTraineesK99/R00 PAR-23-287NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.2/14/24, 6/14/24, 10/14/24https://grants.nih.gov/grants/guide/pa-files/PAR-23-287.html10/15/26
64
NIHTraineesK99/R00 PAR-23-286NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.2/14/24, 6/14/24, 10/14/24https://grants.nih.gov/grants/guide/pa-files/PAR-23-286.html10/15/26
65
NCIFacultyR01 PAR-24-085National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)This NOFO is soliciting research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM. The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may propose to conduct an early phase trial by itself, or in combination with another research aim(s) as appropriate. This NOFO does not accept Phase III clinical trials.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-24-085.html1/8/27
66
NCIFacultyR01 PAR-24-072Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)This NOFO invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html1/8/27
67
NIHFacultyR01 PAR-23-244Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)This NOFO aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-23-244.html1/8/27
68
NIHFacultyR01 PAR-23-170Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)THis NOFO solicits applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Interventions should include screening, preventive services, or other healthcare processes, including timely follow-up of abnormal findings, and referral to accessible care.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-23-170.html1/8/27
69
NCIFacultyR25 PAR-23-276Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed)The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-23-276.html1/8/27
70
NCIFacultyR25 PAR-23-277Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-23-277.html1/8/27
71
NCIFacultyR25 PAR-23-278Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed)This FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.Standard dates applyhttps://grants.nih.gov/grants/guide/pa-files/PAR-23-278.html1/8/27
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105